Study shows mirabegron effective and well tolerated for overactive bladder

In a new phase III trial mirabegron, a beta3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group. The incidence of common adverse events (hypertension, urinary tract infection, headache, nasopharyngitis) was similar in the mirabegron and placebo groups. Rates of dry mouth and constipation were similar in the drug …

Fuente : http://www.eurekalert.org/pub_releases/2013-03/ehs…